IMA vs. LYEL, MNPR, TRDA, TLSA, HRTX, KRRO, VYGR, SLS, RAPT, and EPRX
Should you be buying ImageneBio stock or one of its competitors? The main competitors of ImageneBio include Lyell Immunopharma (LYEL), Monopar Therapeutics (MNPR), Entrada Therapeutics (TRDA), Tiziana Life Sciences (TLSA), Heron Therapeutics (HRTX), Korro Bio (KRRO), Voyager Therapeutics (VYGR), SELLAS Life Sciences Group (SLS), Rapt Therapeutics (RAPT), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "pharmaceutical products" industry.
ImageneBio vs. Its Competitors
ImageneBio (NASDAQ:IMA) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.
ImageneBio has higher revenue and earnings than Lyell Immunopharma. ImageneBio is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
ImageneBio has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -552,328.31%. ImageneBio's return on equity of -23.94% beat Lyell Immunopharma's return on equity.
ImageneBio currently has a consensus price target of $35.50, indicating a potential upside of 298.43%. Lyell Immunopharma has a consensus price target of $15.00, indicating a potential upside of 14.77%. Given ImageneBio's stronger consensus rating and higher possible upside, research analysts clearly believe ImageneBio is more favorable than Lyell Immunopharma.
75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 5.9% of ImageneBio shares are owned by company insiders. Comparatively, 22.3% of Lyell Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
ImageneBio has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.19, indicating that its share price is 119% less volatile than the S&P 500.
In the previous week, Lyell Immunopharma had 2 more articles in the media than ImageneBio. MarketBeat recorded 6 mentions for Lyell Immunopharma and 4 mentions for ImageneBio. Lyell Immunopharma's average media sentiment score of 0.88 beat ImageneBio's score of 0.20 indicating that Lyell Immunopharma is being referred to more favorably in the news media.
Summary
ImageneBio beats Lyell Immunopharma on 11 of the 16 factors compared between the two stocks.
Get ImageneBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImageneBio Competitors List
Related Companies and Tools
This page (NASDAQ:IMA) was last updated on 9/10/2025 by MarketBeat.com Staff
